New drug delivery method for treating sarcoma
Official title: Innovative Drug Delivery Nanophotonic Platform for Implementation of Sarcoma Therapy
Run by Istituto Ortopedico Rizzoli · NCT06599957 · Data updated 2026-11-12
This study is testing a new way to deliver cancer treatment directly to hard-to-reach sarcoma tumors using tiny particles and light to see if it works better for patients with inoperable tumors.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 2 Years to 85 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Istituto Ortopedico Rizzoli Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Bologna, Emilia-Romagna and 1 other locations) |
| Status | Recruiting |
| Started | August 30, 2024 |
| Main results expected | August 30, 2026 |
| Study ends | August 30, 2026 |
| Registry record updated | September 22, 2025 |
| Trial ID | NCT06599957 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients aged 0 to 85 years with soft tissue sarcomas or bone sarcomas, including osteosarcomas, who are undergoing surgery or biopsy.
✕Probably not a fit
Patients not affected by soft tissue sarcomas or bone sarcomas, as well as those with multiple primary tumors, will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to enhance sarcoma therapy through the development of a novel nanophotonic delivery system designed for patients with inoperable tumors or oligometastases. The approach involves creating innovative nanocarriers loaded with chemotherapeutic agents, which will be delivered more effectively using an optic fiber technique known as optoporation. Following the synthesis and characterization of these nanoparticles, a prototype will be produced and validated preclinically using patient-derived biological material. This comprehensive methodology is intended to generate robust data that can be rapidly translated into clinical applications.
Why it matters
Potential benefit: If successful, this innovative delivery method could significantly improve treatment outcomes for patients with difficult-to-treat sarcomas.
How similar studies have gone: While this approach is innovative, similar studies exploring nanocarrier systems have shown promise, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients eligible for the study will be male or female, with an age ranging from 0- to 85 years, undergoing surgery or biopsy for STSs or BSs including osteosarcomas. * Included patients may have undergone or may be still in treatment with chemotherapy (also neo-adjuvant settings), targeted therapy, radiotherapy, or combination therapy. * IRST will enroll only adult patients (age \> 18 years). * Signed informed consent from all subjects enrolled in the study. IOR patients will have to sign both the specific project Informed Consent and the IOR Biobank Informed consent. Exclusion Criteria: * Patients not affected by STSs or BSs will be excluded from the study, as well as patients with multiple primary tumors.
Where it's running
-
Istituto Ortopedico Rizzoli-OSOTT
Bologna, Emilia-Romagna, Italy Recruiting -
IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
Meldola, Emilia-Romagna, Italy Recruiting
Study contacts
- Study coordinator: Toni Ibrahim, MD Oncologist
- Email: toni.ibrahim@ior.it
- Phone: +39 0516366199
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gene-based grouping of bone and soft tissue tumors
This study tests whether tumors of bone and soft tissue can be sorted into clearer genetic groups using DNA and RNA data.
-
Patient-derived 3D tumor models for sarcoma and metastases
This project will try to turn leftover tumor and blood samples from people with sarcoma or with bone or lung metastases into lab-grown 3D tumor models to help test new treatments.
-
QL1706 treatment for advanced bone and soft tissue sarcoma
This will try QL1706 in adults with advanced or metastatic bone and soft tissue sarcomas to see if it controls tumor growth and is well tolerated.
-
Collecting data on bone and soft tissue tumors
This study is collecting information from patients with bone and soft tissue tumors at Henan Cancer Hospital over the next ten years to see how their treatment and outcomes change over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.